Authors

Latest:

Dr. Murphy on Future Research Efforts With Pazopanib Plus SBRT in Pediatric Sarcoma

Erin Murphy, MD, discusses future research efforts with pazopanib plus stereotactic body radiation therapy in patients with pediatric sarcoma.

Erin Wysong Hofstatter, MD

Latest:

Dr. Hoftstatter on Impact of Molecular Testing on Genetic Abnormalities in Breast Cancer

Erin Wysong Hofstatter, MD, associate professor, co-director, Cancer Genetics and Prevention Program, Yale Cancer Center, discusses what impact the advancements with molecular testing have had on the identification of genetic abnormalities in patients with breast cancer.

Erlene Seymour, MD

Latest:

Dr. Seymour on Investigational BTK Inhibitors in CLL

Erlene Seymour, MD, discusses investigational BTK inhibitors in chronic lymphocytic leukemia.

Erminia Massarelli, MD, PhD

Latest:

NSCLC: Future Treatment Landscape of EGFR Exon 20 Insertion Mutations

Before closing out their discussion on EGFR exon 20 insertion mutations in NSCLC, experts share their thoughts on the future treatment landscape and potential unmet needs.

Eugene B. Cone, MD

Latest:

Dr. Cone on Research Investigating Cardiac Toxicity of GnRH Agonists/Antagonists in Prostate Cancer

Eugene B. Cone, MD, a urologic oncology fellow at Brigham and Women’s Hospital and Massachusetts General Hospital, discusses research investigating the cardiac toxicity of gonadotropin-releasing hormone (GnRH) agonists and antagonists in prostate cancer.

Eugene Feit

Latest:

The Downside to Beating the Odds

By now, I am supposed to be dead.

Eugene J. Koay, MD, PhD, MD Anderson Cancer Center

Latest:

Novel Targeted Therapies Under Investigation in Biliary Tract Cancers

Comprehensive insight on novel targeted agents under investigation in the setting of biliary tract cancers.

Eugene Y. Rhee, MD

Latest:

Dr. Rhee Discusses Workplace Violence in Urology Practices

Eugene Y. Rhee, MD, chief of urology, Kaiser Permanente, discusses workplace violence in urology practices.

Eunice Wang, MD

Latest:

Dr Wang on Ziftomenib Plus Intensive Induction in Newly Diagnosed, NPM1+ or KMT2A+ AML

Eunice S. Wang, MD, on ziftomenib plus intensive induction in newly diagnosed, NPM1-mutated or KMT2A-rearranged acute myeloid leukemia.

Eunice Wang, MD, Roswell Park Cancer Institute

Eunice Wang, MD, Roswell Park Comprehensive Cancer Center

Latest:

Optimizing Treatment Selection for Patients with FLT3-ITD AML

Discussion centered around optimal strategies to effectively treat, and improve outcomes for, patients with FLT3-ITD AML.

Eva Comperat, MD

Latest:

Dr. Comperat on the Treatment Strategy for Neuroendocrine Tumors

Eva Comperat, MD, Hospital Tenon, discusses the treatment strategy for patients with neuroendocrine tumors (NETs).

Evan R. Goldfischer, MD, MBA, FACS

Latest:

Dr. Goldfischer on Integrated Medical Groups

Evan R. Goldfischer, MD, MBA, FACS, director of the Research Department at Premier Medical Group of the Hudson Valley, discusses the benefits of integrated medical groups.

Evan W. Alley, MD, PhD

Latest:

Dr. Evan Alley on KEYNOTE-028 Trial Results in Mesothelioma

Evan W. Alley, MD, PhD, discusses the results from the phase Ib KEYNOTE-028 trial on a cohort of patients with malignant pleural mesothelioma.

Evan Wu, MD

Latest:

Metastatic Cancer Is a Chronic Condition

Advancements in targeted therapy and immunotherapy have led to a rapidly increasing number of patients with metastatic cancer becoming patients with chronic cancer.

Evan Y. Yu, MD

Latest:

Key Takeaways on Updates in Bladder Cancer

Elizabeth Plimack, MD, MS, FASCO, recaps the discussion with key takeaways on recent updates in bladder cancer.

Evan Y. Yu, MD, Fred Hutchinson Cancer Research Center

Latest:

Overview of Improvements in Prostate Cancer Management

Broad discussion on the evolution of care in prostate cancer from both the therapeutic and imaging standpoints.

Evan Y. Yu, MD, Seattle Cancer Care

Evan Y. Yu, MD, Seattle Cancer CareÂ Â

Evan Yu, MD, University of Washington